


<b>Comp.</b>	<b>R</b>	<b>R1</b>	<b>Comp.</b>	<b>R</b>	<b>R1</b>
<b>1A</b>	CH <sub>3</sub>		<b>2A</b>	C <sub>2</sub> H <sub>5</sub>	
<b>1B</b>	CH <sub>3</sub>		<b>2B</b>	C <sub>2</sub> H <sub>5</sub>	
<b>1C</b>	CH <sub>3</sub>		<b>2C</b>	C <sub>2</sub> H <sub>5</sub>	
<b>1D</b>	CH <sub>3</sub>		<b>2D</b>	C <sub>2</sub> H <sub>5</sub>	
<b>1E</b>	CH <sub>3</sub>		<b>2E</b>	C <sub>2</sub> H <sub>5</sub>	
<b>1F</b>	CH <sub>3</sub>		<b>2F</b>	C <sub>2</sub> H <sub>5</sub>	
<b>1G</b>	CH <sub>3</sub>		<b>2G</b>	C <sub>2</sub> H <sub>5</sub>	

**Figure S1.** Structure of 1H-pyrollo[3,4-c]pyridine-1,3(2H)-dione derivatives previously published discussed in the text (**1A-F,2A-F**). Part I.



Comp.	R	n	R1	Comp.	R	n	R1
1H	CH <sub>3</sub>	3		1Q	CH <sub>3</sub>	4	
1I	CH <sub>3</sub>	3		1P	CH <sub>3</sub>	4	
1J	CH <sub>3</sub>	3		1R	CH <sub>3</sub>	4	
1K	CH <sub>3</sub>	1		2H	C <sub>2</sub> H <sub>5</sub>	3	
1L	CH <sub>3</sub>	1		2I	C <sub>2</sub> H <sub>5</sub>	3	
1M	CH <sub>3</sub>	1		2J	C <sub>2</sub> H <sub>5</sub>	3	
1N	CH <sub>3</sub>	4					

**Figure S2.** Structure of 1*H*-pyrrolo[3,4-*c*]pyridine-1,3(2*H*)-dione derivatives previously published discussed in the text(1*H*-R,2*H*-J).Part II

**Table S1.** Influence of the compounds investigated on the pain reaction in the “writhing” test in mice.

Compounds	Dose (mg/kg)	Mean no. of writhing ± SEM	ED <sub>50</sub> (mg/kg) ± SEM
<b>Control</b>	0	32.2 ± 3.0	
	50	3.8 ± 2.1***	
	25	6.2 ± 0.9**	14.5 ± 0.03
	12.5	19.8 ± 2.1	(11.15-11.28)
<b>Control</b>	0	29.7 ± 30	
	37.5	1.2 ± 0.7****	
	18.75	5.0 ± 2.0****	3.67 ± 0.49
	9.375	9.8 ± 1.8****	(2.82-4.77)
	4.68	22.0 ± 4.6	
<b>Control</b>	0	24.0 ± 2.8	
	100	0.9 ± 0.1****	
	50	2.1 ± 0.6****	15.8 ± 0.91
	25	7.9 ± 2.1**	(14.1-17.7)
<b>Control</b>	0	29.7 ± 3.0	
	50	1.4 ± 0.6 ****	
	12.5	4.3 ± 1.1 ****	3.25 ± 0.80
	6.25	6.0 ± 2.8 ****	(2.01-5.16)
	3.125	17.7 ± 2.4*	
<b>Control</b>	0	24.0 ± 2.8	
	100	1.9 ± 0.4****	
	50	2.4 ± 0.3****	14.9 ± 2.01
	25	9.7 ± 1.1 ****	(11.5-19.4)
	12.5	13.9 ± 2.3	
<b>Control</b>		24.0 ± 2.8	
	100	0.8 ± 0.1****	
	50	3.8 ± 1.9***	14.8 ± 1.40
	25	5.9 ± 0.8**	(12.4-17.9)
	12.5	14.1 ± 1.0	
<b>Control</b>	100	1.8 ± 0.3****	
	50	5.9 ± 1.9***	18.4 ± 1.73
	25	9.1 ± 0.8*	(15.3-22.1)
	12.5	15.1 ± 4.2	
<b>Control</b>	100	1.4 ± 0.4****	
	50	2.9 ± 1.9***	19.2 ± 2.14
	25	9.4 ± 2.2**	(14.3-22.7)
	12.5	17.2 ± 3.2	
<b>ASA</b>	0	19.2 ± 3.2	
	100	3.2 ± 1.1****	
	50	8.5 ± 1.3**	39.15 ± 4.84
	30	11.2 ± 2.1	(29.1-48.1)
<b>Morphine</b>	10	1.2 ± 0.8****	
	3	7.5 ± 2.9**	2.44 ± 0.97
	1	16.2 ± 3.51	(1.18-5.02)


Each group consisted of 6-8 animals. \*\*\*\* P < 0.001, \*\*\*P < 0.01, \*\*P < 0.02, \*P < 0.05.

**Table S2.** Influence of the compounds investigated on the spontaneous locomotor activity in mice.

Compounds	Dose (mg/kg)	Degree of motor inhibition (%)	Number of impulses ± SEM (30min)	ED <sub>50</sub> (mg/kg) ± SEM
Control	0		464 ± 25.9	
	50	61.64****	178 ± 30****	
	25	35.36**	299 ± 59**	34.2 ± 8.50
	12.5	32.76**	312 ± 26**	(21.37-54.72)
	5	18.1	387 ± 24	
Control	0		451 ± 68	
	37.5	67.18****	148 ± 32****	
	18.75	45.90**	244 ± 45****	18.8 ± 4.00
	93.75	42.79*	258 ± 47.4**	(12.5 – 28.2)
	4.68	22.62	22.0 ± 4.6	
Control	0		441 ± 82	
	100	6.8****	142 ± 29****	
	50	55.10***	198 ± 54***	84.0 ± 5.10
	25	49.20**	224 ± 45**	(75 - 95)
Control	0		451 ± 68	
	50	68.74****	141 ± 63 ***	
	25	55.85**	199.1 ± 48 **	19.7 ± 4.89
	12.5	55.43*	201 ± 74*	(12.3 – 31.5)
	6.25	28.16	324 ± 49*	
Control	0		441 ± 82	
	200	76.19****	105 ± 48****	
	100	59.18***	180 ± 41***	85.0 ± 4.20
	50	34.46*	289 ± 72 *	(77-93.5)
	25	11.79	389 ± 54	
Control	0		178 ± 32***	
	200	59.64***	299 ± 49**	164.0 ± 28.72
	100	32.20**	406 ± 34	(117-229.6)
	50	7.93		
	200	65.99***	150 ± 48***	
Control	0		210 ± 40**	
	100	52.38**	280 ± 46*	98.0 ± 13.26
	50	3.5*	394 ± 70	(75.4 -127.4)
	25	10.65		
	200	65.53****	152 ± 34****	
Control	0		203 ± 39***	
	100	53.96***	253 ± 48*	89.1 ± 4.46
	50	42.63*	399 ± 71	(80-97.5)
	25	9.52		

Each group consisted of 6-8 animals. \*\*\*\* P < 0.001, \*\*\*P < 0.01, \*\*P < 0.02, \*P < 0.05.

Table S3. Determination of the ability to displace ligands labeled with tritium dihydromorphine [<sup>3</sup>H-DHM] from the  $\mu$ -receptor binding sites of the rat cortex.



Compounds	R,	R <sub>1</sub>	Dihydromorphine [ <sup>3</sup> H-DHM] Ki [μM]
<b>1I</b>	CH <sub>3</sub> ,		30.8 ± 47.8
<b>2D</b>	C <sub>2</sub> H <sub>5</sub> ,		>100
<b>1J</b>	CH <sub>3</sub> ,		>100
<b>2J</b>	C <sub>2</sub> H <sub>5</sub> ,		> 100
<b>1G</b>	CH <sub>3</sub> ,		>100
<b>1M</b>	CH <sub>3</sub> ,		13.8 ± 12.2